Hoth Therapeutics, Inc. (NASDAQ:HOTH) Sees Significant Increase in Short Interest

Hoth Therapeutics, Inc. (NASDAQ:HOTH) was the target of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 245,300 shares, a growth of 11.8% from the August 31st total of 219,400 shares. Approximately 3.6% of the company’s shares are sold short. Based on an average daily trading volume, of 3,650,000 shares, the short-interest ratio is presently 0.1 days.

Hoth Therapeutics Trading Up 3.4 %

NASDAQ HOTH traded up $0.03 during trading on Friday, hitting $0.91. The company had a trading volume of 154,025 shares, compared to its average volume of 1,461,274. Hoth Therapeutics has a one year low of $0.58 and a one year high of $1.73. The company has a market cap of $4.87 million, a price-to-earnings ratio of -0.47 and a beta of 0.82. The company’s fifty day moving average is $0.82 and its 200-day moving average is $1.03.

Hoth Therapeutics (NASDAQ:HOTH) last issued its quarterly earnings data on Friday, August 9th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.15. As a group, equities analysts anticipate that Hoth Therapeutics will post -1.18 EPS for the current year.

Wall Street Analyst Weigh In

HOTH has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Hoth Therapeutics in a research report on Friday, August 16th. EF Hutton Acquisition Co. I upgraded shares of Hoth Therapeutics to a “strong-buy” rating in a report on Wednesday, August 21st.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.